Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Treatment Response Biomarkers in Asthma and COPD

Publikation: Bidrag til tidsskriftReviewForskningpeer review

DOI

  1. Effect of Liraglutide on Vascular Inflammation Evaluated by [64Cu]DOTATATE

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Optimal Insertion Depth for Nasal Mid-Turbinate and Nasopharyngeal Swabs

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Infrared Thermography as a Method of Verification in Raynaud's Phenomenon

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Four-Dimensional Flow MRI of Abdominal Veins: A Systematic Review

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  1. The Association between Use of ICS and Psychiatric Symptoms in Patients with COPD—A Nationwide Cohort Study of 49,500 Patients

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Heart failure associated with imported malaria: a nationwide Danish cohort study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Alfa-1 Antitrypsinmangel

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  4. Hydroxychloroquine as a primary prophylactic agent against sars-cov-2 infection: a cohort study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer
Chronic obstructive pulmonary disease (COPD) and asthma are two of the most common chronic diseases worldwide. Both diseases are heterogenous and complex, and despite their similarities, they differ in terms of pathophysiological and immunological mechanisms. Mounting evidence supports the presence of several phenotypes with various responses to treatment. A systematic and thorough assessment concerning the diagnosis of both asthma and COPD is crucial to the clinical management of the disease. The identification of different biomarkers can facilitate targeted treatment and monitoring. Thanks to the presence of numerous immunological studies, our understanding of asthma phenotypes and mechanisms of disease has increased markedly in the last decade, and several treatments with monoclonal antibodies are available. There are compelling data that link eosinophilia with an increased risk of COPD exacerbations but a greater treatment response and lower all-cause mortality. Eosinophilia can be considered as a treatable trait, and the initiation of inhaled corticosteroid in COPD patients with eosinophilia is supported in many studies. In spite of advances in our understanding of both asthma and COPD in terms pathophysiology, disease mechanisms, biomarkers, and response to treatment, many uncertainties in the management of obstructive airways exist.
OriginalsprogEngelsk
Artikelnummer1668
TidsskriftDiagnostics
Vol/bind11
Udgave nummer9
ISSN2075-4418
DOI
StatusUdgivet - 13 sep. 2021

ID: 67654133